[Immunization with synthetic peptide anti-tick Rhipicephalus (Boophilus) microplus SBm7462 via mucosal routes]

The mucosal immunization consists on antigen administration in these surfaces it is a not invasive method, inductor of local and systemic immune response. This work evaluated the immune response of the synthetic vaccine anti-tick Rhipicephalus (Boophilus) microplus SBm7462®, via oral and nasal routes. Were used 60 BALB/c mice, divided in three groups of 20 animals each (I: oral immunization; II: nasal immunization; III: animals not immunized). Nine and 15 days after the first and the second immunization was collected, separately for each group, T cells from the immunized animals, cultivating them per 10 days. After the incubation, were determined the percentage of cellular viability and the specific nature of this T cells, which had held as memory T cell. The averages of T cell SBm7462-reagents had been submitted to the analysis of variance and comparison for Tukey test, 5% of probability. Group II presented higher cellular proliferation "in vitro". For ELISA test, were positive only two animals in group I and eight in group II. The oral and nasal routs alternatively viable for immunization with the synthetic peptide SBm7462®, however require greater number of doses to induce responses with high levels of immunoglobulins.